Your session is about to expire
← Back to Search
MT-0169 for Multiple Myeloma
Study Summary
This trial is testing MT-0169, an investigational drug that recognizes and binds to the CD38 receptor on cancer cells, delivering a modified toxin that kills the cells.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had myelodysplastic syndrome or another type of cancer, except for certain exceptions.You have amyloidosis in any organ, or amyloid on the bone marrow biopsy without other signs of amyloidosis.If you have any of these heart problems.You have multiple myeloma and have not responded well to or cannot tolerate the currently available treatments that have shown to be effective.You have not fully recovered from side effects of previous treatments, except for hair loss and stable mild nerve pain.You have been diagnosed with multiple myeloma using specific diagnostic criteria.You have a disease that can be measured.You have a performance score of 0 or 1 according to the Eastern Cooperative Oncology Group.This criterion refers to specific cardiovascular measurements or indicators that will be used to determine eligibility for the clinical trial. The details of the parameters would need to be specified to provide a clear explanation.It looks like the criterion is incomplete. Could you please provide more details or the complete criterion for me to rewrite it in a simplified form?You have certain blood and nerve-related conditions like POEMS syndrome, amyloidosis, or Waldenström macroglobulinemia.You have received a live vaccine within 28 days before the first dose of MT-0169.You have had serious fluid build-up around your lungs or heart in the past 3 months.You have a long-lasting or current infection that needs medication, or you had a serious viral infection that hasn't completely healed.You have a type of cancer called RRMM and have not responded well to standard treatments or cannot tolerate them.You have had a transplant using stem cells or an organ from someone else.You have a long-term condition that requires taking more than 10mg of prednisone or an equivalent medication every day.You have had a bad reaction to kanamycin or similar medications in the past.You have been diagnosed with multiple myeloma based on specific criteria.Your blood or urine tests don't show the specific protein levels needed for the study, especially if you have the disease in other parts of your body.You have a disease that can be measured.You have severe nerve problems causing issues with feeling or movement.You have not fully recovered from side effects of past myeloma treatments or procedures, except for hair loss and mild nerve problems.You have symptoms that show your central nervous system is involved in the disease.You have a medical or mental illness that would make it hard for you to take part in the study or be evaluated, such as uncontrolled medical conditions, active infection, or serious liver or lung diseases.You have had a serious inflammatory reaction after receiving certain types of antibody or CAR T therapy.
- Group 1: Part 1: Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have signed up for the experiment?
"Affirmative. As indicated on clinicaltrials.gov, the trial that was initially posted back in February 5th 2020 is actively seeking applicants. This research requires 144 patients to be recruited across 7 sites."
How have patients reacted to the MT-0169 drug regimen?
"MT-0169's safety is rated as a 1, due to the fact that it is still in Phase 1 and has yet to have sufficient efficacy or safety data collected."
Is this research endeavor actively recruiting participants?
"Per the clinicaltrials.gov website, this trial is currently recruiting participants and was initially posted on February 5th 2020 with a most recent edit on September 6th 2022."
How many sites are currently overseeing this clinical experiment?
"Currently, seven medical centres are recruiting participants for this study. These institutions include Miami University in Miami, Northside Hospital in Atlanta and Indiana University in Indianapolis."
Share this study with friends
Copy Link
Messenger